Perineural Invasion and Perineural Spread in Ophthalmic Oncology
All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.
Perineural invasion and perineural spread are important high-risk features in ophthalmic oncology. Perineural invasion refers to tumor involving a nerve on histopathology, whereas perineural spread refers to clinical or radiographic tumor extension along a larger named nerve. These processes are especially relevant in periocular cutaneous malignancies, lacrimal gland tumors, and head and neck cancers with orbital or skull-base involvement. Recognition is important because perineural disease may be subtle initially but can lead to delayed diagnosis, local recurrence, orbital apex or cavernous sinus involvement, skull-base extension, and poor prognosis.[1][2][3]
Disease Entity
Perineural invasion and perineural spread are related but distinct forms of tumor-nerve involvement. Perineural invasion is primarily a histopathologic finding, while perineural spread is usually recognized clinically or radiographically when tumor extends along a larger named nerve pathway.[1]
In ophthalmic oncology, perineural disease is most often discussed in periocular cutaneous malignancies, lacrimal gland tumors, and head and neck malignancies that involve the orbit, cranial nerves, skull base, or cavernous sinus.[2][3] Recognition is important because perineural disease may be associated with treatment failure, local recurrence, orbital or intracranial extension, and worse prognosis.[2]
Disease
Perineural invasion describes tumor cells involving a nerve on pathology. Perineural spread describes tumor extension along a larger named nerve pathway, often producing neurologic symptoms or imaging abnormalities.[1] These findings may be microscopic near the primary tumor or may extend proximally toward the orbit, skull base, cavernous sinus, or intracranial compartment.
Perineural invasion and spread are important in ophthalmology because nerve involvement may explain symptoms that are not obvious from the visible tumor alone. Patients may present with pain, numbness, reduced corneal sensation, ocular surface disease, diplopia, ophthalmoplegia, facial weakness, or findings of Orbital Apex Syndrome or Cavernous Sinus Syndrome.[3]
Etiology
Perineural disease may occur in several ophthalmic and periocular malignancies. Important examples include periocular squamous cell carcinoma, basal cell carcinoma, sebaceous carcinoma, melanoma, and adenoid cystic carcinoma of the lacrimal gland.[2][3] It may also occur in head and neck malignancies that extend toward the orbit, skull base, or cranial nerves.[3]
Periocular squamous cell carcinoma is one of the most clinically important causes because perineural invasion is a recognized high-risk feature and may affect staging, treatment planning, recurrence risk, and prognosis.[2] Adenoid cystic carcinoma of the lacrimal gland is also classically associated with perineural invasion and may spread along nerves despite initially subtle clinical findings.[4]
Risk Factors
Risk factors depend on the underlying tumor type. In periocular squamous cell carcinoma, perineural invasion is more concerning when associated with recurrent disease, larger tumor size, increased tumor thickness, poor differentiation, immunosuppression, positive margins, or involvement of larger named nerves.[2] Clinical or radiographic perineural spread is generally more concerning than incidental microscopic perineural invasion because it suggests more extensive nerve pathway involvement.[1][5]
Other concerning features include tumor location near major sensory or motor nerves, orbital invasion, skull-base extension, recurrent disease after prior surgery or radiation, and symptoms that localize to the trigeminal or facial nerve pathways.[3]
General Pathology
On histopathology, perineural invasion refers to tumor cells tracking around, along, or within a nerve.[1] Pathology reports should describe the presence or absence of perineural invasion when identified. When possible, reports should also comment on features that may affect risk stratification, including nerve caliber, named nerve involvement, multifocality, depth of invasion, tumor differentiation, lymphovascular invasion, and margin status.[1][2]
Perineural invasion should be distinguished from perineural spread. Perineural invasion may be microscopic and detected only on histologic examination. Perineural spread usually refers to clinically or radiographically apparent tumor extension along a larger nerve pathway.[1] This distinction is important because microscopic perineural invasion and radiographic perineural spread may have different implications for imaging, staging, treatment, and prognosis.
Pathophysiology
Perineural invasion was historically viewed as tumor extension through a low-resistance anatomic space. Current evidence suggests a more active process involving interaction between tumor cells and the nerve microenvironment.[6] Tumor cells, Schwann cells, stromal cells, immune cells, extracellular matrix components, and soluble signaling molecules may contribute to tumor survival, adhesion, migration, and invasion along nerves.[6]
In cutaneous squamous cell carcinoma, gene-expression studies suggest that tumors with perineural invasion may have distinct molecular changes, including alterations involving the p53 pathway.[7] These findings support the concept that perineural invasion is not simply passive tumor tracking, but may reflect biologically aggressive tumor behavior.
In ophthalmic oncology, clinically important pathways include branches of the trigeminal nerve and facial nerve. Tumor may extend along the supraorbital, supratrochlear, infraorbital, nasociliary, lacrimal, infraorbital, or mandibular nerve pathways and may progress toward the superior orbital fissure, foramen rotundum, foramen ovale, Meckel cave, cavernous sinus, or skull base.[3][8]
Primary Prevention
There is no specific primary prevention strategy for perineural invasion or perineural spread independent of preventing and detecting the underlying malignancy. For periocular cutaneous malignancies, prevention includes ultraviolet protection, early evaluation of suspicious eyelid or periocular lesions, appropriate biopsy, and definitive treatment of high-risk or recurrent tumors.
Early recognition of high-risk pathology and symptoms concerning for perineural spread may help reduce delays in diagnosis and treatment.
Diagnosis
Diagnosis requires integration of history, ophthalmic examination, pathology, and imaging. Perineural invasion may be found incidentally on pathology, whereas perineural spread is often suspected because of symptoms, cranial nerve abnormalities, or imaging findings along a named nerve pathway.[1][3]
A normal or nonspecific initial examination or imaging report does not exclude perineural spread when the clinical localization remains concerning. Suspicion should remain high when symptoms progress, when multiple cranial nerves are involved, or when the examination localizes to the orbit, skull base, cavernous sinus, or trigeminal/facial nerve pathways.[3]
History
History should include prior eyelid, periocular, facial, scalp, lacrimal gland, sinus, or head and neck malignancy. Prior Mohs surgery, excision, radiation therapy, recurrence, margin status, and pathology reports documenting perineural invasion should be reviewed.[2][3]
Symptoms concerning for perineural spread include new or progressive facial numbness, pain, paresthesia, diplopia, ptosis, facial weakness, decreased tearing, ocular surface irritation, or nonhealing epithelial disease.[3] Symptoms may develop months to years after treatment of the original tumor.
Physical Examination
Examination should include visual acuity, pupils, ocular motility, eyelid position and closure, slit-lamp evaluation of the ocular surface, corneal sensation, facial sensation, facial nerve function, and regional lymph node examination.[3] The clinician should specifically assess trigeminal nerve function, especially V1 and V2 sensation, and facial nerve function when eyelid closure or blink is abnormal.
Reduced corneal sensation, neurotrophic keratopathy, exposure keratopathy, ophthalmoplegia, ptosis, trigeminal sensory loss, or facial weakness should raise concern for perineural disease in a patient with current or prior periocular or head and neck malignancy.[3]
Signs
Signs of perineural disease depend on the involved nerve pathway. Trigeminal involvement may cause decreased facial sensation, reduced corneal sensation, neurotrophic keratopathy, or facial pain. Facial nerve involvement may cause orbicularis weakness, lagophthalmos, exposure keratopathy, or facial weakness.[3]
Orbital apex or cavernous sinus involvement may cause ophthalmoplegia, ptosis, optic neuropathy, pupillary abnormalities, or multiple cranial neuropathies.[3] These findings should prompt consideration of perineural spread, especially in patients with a history of periocular, facial, lacrimal gland, or head and neck malignancy.
Symptoms
Symptoms may include facial numbness, tingling, pain, burning, diplopia, ptosis, blurred vision, eye redness, foreign body sensation, tearing, dryness, poor eyelid closure, or nonhealing corneal epithelial defects.[3]
Pain or numbness in the distribution of a prior skin cancer should be considered a warning sign, especially when progressive or associated with diplopia, ptosis, ophthalmoplegia, or facial weakness.
Clinical Diagnosis
Perineural spread should be suspected when a patient with current or prior periocular, facial, lacrimal gland, or head and neck malignancy develops progressive sensory symptoms, unexplained ocular surface disease from reduced corneal sensation, facial weakness, diplopia, ophthalmoplegia, or signs of orbital apex or cavernous sinus involvement.[3][9]
Suspicion should be higher when symptoms progress despite treatment for more common conditions, or when the clinical examination localizes to a cranial nerve pathway not adequately explained by routine imaging. Perineural spread may mimic benign or inflammatory neuro-ophthalmic conditions, particularly early in the disease course.
Diagnostic Procedures
Diagnostic evaluation may include review of prior pathology, repeat biopsy of suspicious lesions, targeted nerve biopsy in selected cases, and dedicated orbital/skull-base imaging.[2][3] Pathology review should assess whether perineural invasion was present in the original tumor, whether margins were involved, and whether a named nerve or large-caliber nerve was affected.
Magnetic resonance imaging with contrast is generally preferred when perineural spread is suspected.[2][8] Imaging should be tailored to the suspected nerve pathway and should evaluate the orbit, skull base, foramina, Meckel cave, cavernous sinus, and involved trigeminal or facial nerve branches. Findings may include abnormal nerve enhancement, nerve enlargement, loss of normal fat planes, foraminal widening, muscle denervation changes, or extension into the orbital apex or cavernous sinus.[10]
Meckel cave is an important region to evaluate when trigeminal perineural spread is suspected. Imaging findings that may suggest disease in this region include abnormal enhancement, nerve enlargement, effacement of normal fat planes, foraminal erosion or enlargement, and loss of normal cerebrospinal fluid signal around the trigeminal nerve.[11]
Computed tomography may be useful for assessing bony foraminal widening or skull-base destruction. PET/CT may be useful in selected cases for systemic staging or treatment planning, depending on the underlying malignancy and clinical context.[12]
Laboratory Test
There is no specific laboratory test for perineural invasion or perineural spread. Laboratory testing may be used when the differential diagnosis includes infection, inflammation, systemic malignancy, or other mimicking conditions. Tissue diagnosis and imaging are usually more important than laboratory testing when perineural disease is suspected.
Differential Diagnosis
The differential diagnosis depends on the clinical presentation. Painful ophthalmoplegia or cavernous sinus involvement may mimic inflammatory orbital disease, Tolosa-Hunt syndrome, cavernous sinus thrombosis, infection, lymphoma, metastatic disease, meningioma, schwannoma, or other skull-base tumors.[3]
Isolated cranial neuropathy may mimic microvascular cranial nerve palsy, especially when early imaging is unrevealing. Neurotrophic keratopathy or exposure keratopathy may be misattributed to dry eye disease, herpetic disease, prior surgery, or facial nerve palsy unless corneal sensation and cranial nerve function are carefully assessed.
Management
Management depends on the tumor type, extent of nerve involvement, margin status, orbital or skull-base extension, prior treatment, and patient comorbidities.[2][3] Care is often multidisciplinary and may involve ophthalmology, oculoplastics, ocular oncology, dermatology, head and neck surgery, pathology, radiology, radiation oncology, medical oncology, and neuro-ophthalmology.
General Treatment
Treatment may include surgery, radiation therapy, systemic therapy, or a combination of modalities. Microscopic perineural invasion near the primary tumor may alter risk stratification and adjuvant treatment decisions.[2] Clinical or radiographic perineural spread may require broader treatment planning because tumor can extend beyond the visible lesion along nerve pathways.[3]
Radiation therapy may be considered for high-risk perineural invasion, positive margins, recurrent disease, unresectable disease, or radiographic perineural spread. Treatment fields may need to account for involved nerve pathways and potential skull-base routes of spread.
Treatment should be individualized based on tumor histology, extent of disease, surgical resectability, prior treatment, patient functional status, and multidisciplinary recommendations.
Medical Therapy
Medical therapy depends on the underlying malignancy. Systemic therapy may be considered in selected patients with unresectable, recurrent, advanced, or metastatic disease. The choice of therapy depends on tumor histology, molecular features, disease extent, prior treatment, and multidisciplinary oncology recommendations.
Medical therapy may also be needed to manage ocular surface complications. Supportive treatment may include lubrication, eyelid taping, punctal occlusion, bandage contact lens, amniotic membrane, tarsorrhaphy, or other measures for neurotrophic or exposure keratopathy, depending on severity.
Medical Follow-up
Medical follow-up should monitor for tumor recurrence, progression along nerve pathways, regional nodal disease, distant metastasis, treatment response, and treatment-related complications. Patients should be asked about new pain, numbness, diplopia, facial weakness, ocular surface symptoms, or visual decline.
Follow-up may include repeat clinical examination, cranial nerve assessment, regional lymph node examination, and interval imaging when clinically indicated.
Surgery
Surgical management may include excision of the primary tumor, Mohs micrographic surgery for selected cutaneous tumors, margin-controlled excision, orbital surgery, nerve biopsy, or exenteration in advanced cases.[2][3] Surgical planning should account for the possibility that clinically visible tumor may underestimate the proximal extent of perineural disease.
When perineural spread is suspected, surgery should be planned with attention to the involved nerve pathway, margin status, orbital extension, and skull-base involvement. In selected cases, biopsy of an involved nerve may establish the diagnosis.[13]
Surgical Follow-up
Surgical follow-up should assess wound healing, local recurrence, margin status, ocular surface protection, eyelid position, cranial nerve function, and symptoms suggesting proximal perineural progression. Patients with high-risk pathology or clinical perineural spread often require long-term surveillance.
Follow-up should be coordinated with the appropriate oncology, radiation oncology, dermatology, oculoplastics, ocular oncology, and neuro-ophthalmology teams.
Complications
Complications of perineural disease may include local recurrence, orbital invasion, skull-base extension, cavernous sinus involvement, multiple cranial neuropathies, neurotrophic keratopathy, exposure keratopathy, optic neuropathy, regional metastasis, and disease-related mortality.[2][3]
Treatment may also cause ocular complications, including radiation-related ocular surface disease, cataract, retinopathy, optic neuropathy, eyelid malposition, poor wound healing, or orbital tissue changes.[3]
Prognosis
Perineural invasion and perineural spread are generally adverse prognostic features.[2][1] Prognosis depends on the primary tumor type, size and caliber of the involved nerve, named nerve involvement, margin status, recurrence, immune status, orbital or intracranial extension, nodal disease, and response to treatment.[2][5]
Clinical or radiographic perineural spread is usually more concerning than incidental microscopic perineural invasion because it suggests more extensive disease. Early recognition is important because perineural disease may affect surgical planning, radiation fields, systemic therapy decisions, and surveillance strategy.
Global Variants
Global differences may reflect variation in ultraviolet exposure, skin cancer burden, access to dermatologic care, Mohs surgery, ophthalmic oncology services, high-resolution MRI, radiation therapy, and systemic oncology treatments. Published ophthalmic data are limited, and management should be adapted to local resources and multidisciplinary expertise.
Additional Resources
Related EyeWiki articles include Squamous Carcinoma of the Eyelid, Basal Cell Carcinoma, Sebaceous Carcinoma, Adenoid Cystic Carcinoma of the Lacrimal Gland, Lacrimal Gland Tumors, Orbital Apex Syndrome, Cavernous Sinus Syndrome, Exenteration, Sentinel Lymph Node Biopsy for Periorbital Malignancy, and Targeted Therapies for Periocular Malignancies.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Brown IS. Pathology of perineural spread. J Neurol Surg B Skull Base. 2016;77(2):124-130. doi:10.1055/s-0036-1571837.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 Tong JY, Huilgol SC, James C, Rajak S, Selva D. Perineural invasion and perineural spread in periocular squamous cell carcinoma. Eye (Lond). 2023;37(5):875-884. doi:10.1038/s41433-022-02306-w.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 Ableman TB, Newman SA. Perineural spread of head and neck cancer: ophthalmic considerations. J Neurol Surg B Skull Base. 2016;77(2):131-139. doi:10.1055/s-0036-1582239.
- ↑ Pal SS, Alam MS, Manikantan K, Honavar S. Adenoid cystic carcinoma of the lacrimal gland - a major review. Indian J Ophthalmol. 2025;73(10):1399-1411. doi:10.4103/IJO.IJO_2560_24.
- ↑ 5.0 5.1 Karia PS, Morgan FC, Ruiz ES, Schmults CD. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma: a systematic review and pooled analysis of outcomes data. JAMA Dermatol. 2017;153(8):781-788. doi:10.1001/jamadermatol.2017.1680.
- ↑ 6.0 6.1 Chen SH, Zhang BY, Zhou B, Zhu CZ, Sun LQ, Feng YJ. Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche. Am J Cancer Res. 2019;9(1):1-21. PMID:30755808.
- ↑ Warren TA, Broit N, Simmons JL, Pierce CJ, Chawla S, Lambie DL, Quagliotto G, Brown IS, Parsons PG, Panizza BJ, Boyle GM. Expression profiling of cutaneous squamous cell carcinoma with perineural invasion implicates the p53 pathway in the process. Sci Rep. 2016;6:34081. doi:10.1038/srep34081.
- ↑ 8.0 8.1 Gandhi MR, Panizza B, Kennedy D. The imaging of large nerve perineural spread. J Neurol Surg B Skull Base. 2016;77(2):113-123. doi:10.1055/s-0036-1571836.
- ↑ McNab AA, Francis IC, Benger R, Crompton JL. Perineural spread of cutaneous squamous cell carcinoma via the orbit: clinical features and outcome in 21 cases. Ophthalmology. 1997;104(9):1457-1462.
- ↑ Dankbaar JW, Pameijer FA, Hendrikse J, Schmalfuss IM. Easily detected signs of perineural tumour spread in head and neck cancer. Insights Imaging. 2018;9(6):1089-1095. doi:10.1007/s13244-018-0672-8.
- ↑ Malhotra A, Tu L, Kalra VB, Wu X, Mian A, Mangla R. Neuroimaging of Meckel's cave in normal and disease conditions. Insights Imaging. 2018;9(4):499-510. doi:10.1007/s13244-018-0604-7.
- ↑ Paes FM, Singer AD, Checkver AN, Palmquist RA, De La Vega G, Sidani C. Perineural spread in head and neck malignancies: clinical significance and evaluation with 18F-FDG PET/CT. RadioGraphics. 2013;33(6):1717-1736. doi:10.1148/rg.336135501.
- ↑ Solares CA, Mason E, Panizza BJ. Surgical management of perineural spread of head and neck cancers. J Neurol Surg B Skull Base. 2016;77(2):140-149. doi:10.1055/s-0036-1579751.
